Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600613's EV-to-EBITDA is ranked worse than 86.14% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.305
vs SHSE:600613: 46.71
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shanghai Shenqi Pharmaceutical Investment Management Co's PE Ratio (TTM) for today is calculated as:
Shanghai Shenqi Pharmaceutical Investment Management Co's share price for today is ¥8.56.
Shanghai Shenqi Pharmaceutical Investment Management Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.060.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co EV-to-EBITDA Chart
Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shenqi Pharmaceutical Investment Management Co EV-to-EBITDA vs Drug Manufacturers Industry
Shanghai Shenqi Pharmaceutical Investment Management Co's current Enterprise Value is ¥3,741 Mil.
Shanghai Shenqi Pharmaceutical Investment Management Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a EV-to-EBITDA of 46.71 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co. This is 63% above median its historical median of 28.67. According to the industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #634 out of 736 companies in the Drug Manufacturers industry, placing it in the top 86.1%.
Is Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-EBITDA too high?
Shanghai Shenqi Pharmaceutical Investment Management Co's current EV-to-EBITDA of 46.71 is 63% above median its 10-year median of 28.67. The Drug Manufacturers industry median EV-to-EBITDA is 13.31. Shanghai Shenqi Pharmaceutical Investment Management Co's value of 46.71 is 251.1% above this industry median. Based on the distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #634 out of 736 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shenqi Pharmaceutical Investment Management Co's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Shanghai Shenqi Pharmaceutical Investment Management Co ranks #634 out of 736 companies for EV-to-EBITDA. This places Shanghai Shenqi Pharmaceutical Investment Management Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.31. Shanghai Shenqi Pharmaceutical Investment Management Co's value of 46.71 is 251.1% above this benchmark. While the company's 10-year median is 28.67 vs. the industry median of 13.31, Shanghai Shenqi Pharmaceutical Investment Management Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.31, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Shenqi Pharmaceutical Investment Management Co's current EV-to-EBITDA of 46.71 is 251.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Shenqi Pharmaceutical Investment Management Co's current EV-to-EBITDA is 46.71, which is 63% above median its own 10-year median of 28.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥5.39, compared to a current price of ¥8.56 — trading 58.8% above its estimated fair value. The current EV-to-EBITDA is 46.71, which is 63% above median its 10-year median of 28.67 and 251.1% above the Drug Manufacturers industry median of 13.31. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current EV-to-EBITDA is 46.71 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be overvalued.
The current stock price of ¥8.56 is trading 58.8% above its estimated GF Value™ of ¥5.39.
GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Significantly Overvalued.
Key valuation signals for SHSE:600613:
EV-to-EBITDA: 46.71 (63% above median its 10-year median of 28.67)
GF Value™: ¥5.39 vs. price of ¥8.56 (58.8% above fair value)
Industry Position: 251.1% above the Drug Manufacturers median (#634 of 736)
No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600613 has been successfully added to your 
